Anaplastic thyroid cancer (ATC) is the rarest and most aggressive form of thyroid cancer, accounting for just 1% to 2% of all thyroid cancer cases. It affects roughly one to two people per million per year in the United States. Unlike the more common forms of thyroid cancer, which grow slowly and have excellent survival rates, anaplastic thyroid cancer grows rapidly, invades surrounding structures, and carries a 5-year survival rate of about 10% across all stages.
How It Develops
Anaplastic thyroid cancer is considered “undifferentiated,” meaning the cancer cells no longer resemble or behave like normal thyroid cells. In many cases, it doesn’t arise on its own. Instead, it evolves from a pre-existing, slower-growing thyroid cancer, most commonly papillary thyroid carcinoma. Over time, genetic mutations accumulate and the tumor essentially transforms into a far more dangerous form. Researchers have found conserved genetic changes in both the original papillary tissue and the anaplastic tissue within the same tumor, providing strong evidence of this step-by-step progression.
Several genetic mutations drive this transformation. The BRAF V600E mutation, which is also common in papillary thyroid cancer, appears in 10% to 50% of anaplastic cases. Mutations in the TP53 gene, which normally acts as a brake on uncontrolled cell growth, are frequent and believed to play a central role in the shift from a slow-growing cancer to an aggressive one. Additional mutations in the TERT promoter gene are also common and appear linked to this dedifferentiation process.
Symptoms and How It Presents
The hallmark of anaplastic thyroid cancer is a rapidly growing neck mass. Many patients notice a lump in the front of the neck that enlarges noticeably over weeks rather than months or years. Because the tumor invades nearby structures early, symptoms often include difficulty swallowing, hoarseness or voice changes, and shortness of breath. The cancer frequently invades the trachea and esophagus directly, and bilateral vocal cord paralysis can occur when the nerves controlling the vocal cords are damaged. Airway compromise is one of the most urgent and common complications throughout the course of the disease.
How It Is Diagnosed
Diagnosis typically begins with an ultrasound of the neck, which guides a needle biopsy of the mass. On ultrasound, anaplastic thyroid tumors tend to appear as irregular, poorly defined, dark masses. The biopsy itself reveals tissue that looks strikingly different from normal thyroid cells: large, fleshy, off-white tissue with areas of dead tissue and bleeding. Under the microscope, the tumor shows invasion into blood vessels, and several distinct cell patterns can appear, including spindle-shaped cells, giant cells, and squamous-like cells.
Once a biopsy confirms the diagnosis, imaging is used to determine how far the cancer has spread. CT scans of the neck and chest map local invasion and detect spread to the lungs or mediastinum. PET scans can identify cancer throughout the body, including in lymph nodes, bones, liver, and brain. By the time most patients are diagnosed, the cancer has already spread beyond the thyroid.
Staging Is Different From Other Thyroid Cancers
Unlike papillary or follicular thyroid cancer, which can be staged from I through IV, all anaplastic thyroid cancer is classified as Stage IV at diagnosis. This reflects just how aggressive it is. Within Stage IV, there are subcategories based on how far the cancer has spread: localized disease (confined to the thyroid), regional disease (spread to nearby lymph nodes or structures), and distant disease (spread to organs like the lungs, bones, or brain). The distinction matters because outcomes differ dramatically. Localized anaplastic thyroid cancer has a 5-year survival rate of 45%, while regional disease drops to 14%, and distant disease falls to 5%.
Treatment Options
Treatment depends on whether the tumor can be surgically removed and whether it has spread to distant sites. For patients whose tumor can be fully or nearly fully removed, the standard approach combines surgery with radiation therapy and systemic treatment. Radiation should begin within six weeks of surgery, and chemotherapy can start as early as one week after surgery if healing allows.
For patients whose tumors cannot be surgically removed but haven’t spread to distant organs, a combination of radiation and systemic therapy is the primary approach. The type of radiation used is a precise, targeted form that focuses the beam on the tumor while limiting damage to surrounding healthy tissue.
For tumors that carry the BRAF V600E mutation, targeted therapy has changed the landscape significantly. A combination of two drugs that block the signaling pathway driven by this mutation produced a confirmed response rate of 69% in a clinical trial of 16 patients with locally advanced or metastatic disease. At 12 months, 80% of those patients were still alive, a dramatic improvement over historical outcomes. This targeted approach can be used as an alternative to traditional chemotherapy in BRAF-positive cases, whether or not the tumor is surgically removable.
For patients with widespread disease or poor overall health, the focus often shifts to comfort-oriented care. Airway management becomes a central concern because the tumor frequently compresses or invades the windpipe. Guidelines recommend avoiding tracheostomy as long as possible, but surgeons are often faced with the reality of impending suffocation and must intervene under technically difficult conditions. This remains one of the most challenging ethical and practical aspects of managing the disease.
Prognosis and Survival
Anaplastic thyroid cancer has the worst prognosis of any thyroid malignancy. Across all stages, the 5-year relative survival rate is 10%, based on data from patients diagnosed between 2015 and 2021. Most patients with regional or distant disease survive less than a year. However, outcomes are improving for specific subgroups. Patients with localized disease who undergo aggressive multimodal treatment have meaningfully better prospects, and those with BRAF-mutated tumors now have access to targeted therapies that can produce durable responses where none existed a decade ago.
The speed of diagnosis and treatment initiation matters more in anaplastic thyroid cancer than in almost any other malignancy. Because the tumor can double in size in a matter of weeks, delays in starting therapy directly affect whether surgery remains possible and whether the airway stays open. Early referral to a specialized center with experience managing this rare cancer is one of the most important factors in determining outcomes.